Trillium Therapeutics (Trillium Therapeutics) Debt-to-Asset : 0.00 (As of Sep. 2021)

View and export this data going back to 2009. Start your Free Trial

What is Trillium Therapeutics Debt-to-Asset?

Trillium Therapeutics's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Sep. 2021 was $0.31 Mil. Trillium Therapeutics's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Sep. 2021 was $0.34 Mil. Trillium Therapeutics's Long-Term Debt & Capital Lease ObligationTotal Assets for the quarter that ended in Sep. 2021 was $265.36 Mil. Trillium Therapeutics's debt to asset for the quarter that ended in Sep. 2021 was 0.00.

Trillium Therapeutics Debt-to-Asset Historical Data

The historical data trend for Trillium Therapeutics's Debt-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Trillium Therapeutics Debt-to-Asset Chart

Trillium Therapeutics Annual Data

Trend

Dec11

Dec12

Dec13

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Debt-to-Asset

Get a 7-Day Free Trial

0.04

Trillium Therapeutics Quarterly Data
	Dec16	Mar17	Jun17	Sep17	Dec17	Mar18	Jun18	Sep18	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21
Debt-to-Asset	Get a 7-Day Free Trial															-	-	-	-	-

Competitive Comparison of Trillium Therapeutics's Debt-to-Asset

For the Biotechnology subindustry, Trillium Therapeutics's Debt-to-Asset, along with its competitors' market caps and Debt-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Trillium Therapeutics's Debt-to-Asset Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Trillium Therapeutics's Debt-to-Asset distribution charts can be found below:

* The bar in red indicates where Trillium Therapeutics's Debt-to-Asset falls into.

Trillium Therapeutics Debt-to-Asset Calculation

Debt to Asset measures the financial leverage a company has.

Trillium Therapeutics's Debt-to-Asset for the fiscal year that ended in Dec. 2020 is calculated as

Debt-to-Asset	=	Total Debt			/	Total Assets
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Assets
	=	(0.274	+	0.557)	/	300.822
	=	0.00

Trillium Therapeutics's Debt-to-Asset for the quarter that ended in Sep. 2021 is calculated as

Debt-to-Asset	=	Total Debt			/	Total Assets
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Assets
	=	(0.311	+	0.343)	/	265.36
	=	0.00

Trillium Therapeutics (NAS:TRIL) Debt-to-Asset Explanation

In the calculation of Debt-to-Asset, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Assets.

Trillium Therapeutics Debt-to-Asset Related Terms

Thank you for viewing the detailed overview of Trillium Therapeutics's Debt-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.

Trillium Therapeutics (Trillium Therapeutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Trillium Therapeutics Inc (NAS:TRIL) » Definitions » Debt-to-Asset

Comparable Companies

Traded in Other Exchanges

N/A

Address

100 CambridgePark Drive, Suite 510, Cambridge, MA, USA, 02140

Website

https://www.trilliumtherapeutics.com

Trillium Therapeutics Inc is a clinical-stage immuno-oncology company that is engaged in developing therapies for the treatment of cancer. It has two clinical programs, TTI-621 and TTI-622, that target CD47. The company operates in the United States and Canada.